Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13259740 | 0.83 | ALDH1A1 (0.37) | KMT2AALDH1A1LMNAMAPTHPGD | |
| SCHEMBL10042012 | 0.83 | ALDH1A1 (0.41) | KMT2AALDH1A1LMNAMAPTHPGD | |
| SCHEMBL23435385 | 0.80 | KCNH2 (0.39) | KMT2AALDH1A1LMNAMAPTHPGD | |
| SCHEMBL10682529 | 0.78 | KCNH2 (0.39) | KMT2AALDH1A1LMNAMAPTHPGD | |
| SCHEMBL15998648 | 0.78 | KMT2A (0.36) | KMT2AALDH1A1LMNAMAPTHPGD | |
| SCHEMBL20257615 | 0.77 | SLC6A2 (0.44) | KMT2AALDH1A1LMNAMAPTHPGD | |
| SCHEMBL11264703 | 0.77 | KCNH2 (0.41) | KMT2AALDH1A1LMNAMAPTHPGD | |
| SCHEMBL18786399 | 0.77 | ALDH1A1 (0.33) | KMT2AALDH1A1LMNAMAPTHPGD | |
| SCHEMBL23920793 | 0.77 | KCNH2 (0.41) | KMT2AALDH1A1LMNAMAPTHPGD | |
| SCHEMBL3101172 | 0.75 | ALDH1A1 (0.41) | KMT2AALDH1A1LMNAMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11135296-B2 | Pharmaceutical compositions of fumaric acid esters | ARBOR PHARMACEUTICALS, LLC (US) | 2021-10-05 | — | — | US | disclosed |
| US-20190117776-A1 | Pharmaceutical Compositions of Fumaric Acid Esters | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2019-04-25 | — | — | US | disclosed |
| US-9999672-B2 | Pharmaceutical compositions of fumaric acid esters | XENOPORT, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-20150265707-A1 | PHARMACEUTICAL COMPOSITIONS OF FUMARIC ACID ESTERS | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11135296-B2 | Pharmaceutical compositions of fumaric acid esters | FAH, FH, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | KMT2A 1771/4885ALDH1A1 487/4885LMNA 2691/4885 |
| US-20150265707-A1 | PHARMACEUTICAL COMPOSITIONS OF FUMARIC ACID ESTERS | FAH, FH, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | KMT2A 1771/4885ALDH1A1 487/4885LMNA 2691/4885 |
| US-20190117776-A1 | Pharmaceutical Compositions of Fumaric Acid Esters | FAH, FH, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | KMT2A 1771/4885ALDH1A1 487/4885LMNA 2691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.